BlackRock, Inc. 13D and 13G filings for Nurix Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-04-23 8:57 pm Purchase | 2025-03-31 | 13G | Nurix Therapeutics, Inc. NRIX | BlackRock Inc. BLK | 6,284,116 8.200% | 241,966 (+4.00%) | Filing |
| 2024-06-07 1:30 pm Purchase | 2024-05-31 | 13G | Nurix Therapeutics, Inc. NRIX | BlackRock Inc. BLK | 6,042,150 10.200% | 1,398,414 (+30.11%) | Filing |
| 2024-01-24 2:27 pm Purchase | 2023-12-31 | 13G | Nurix Therapeutics, Inc. NRIX | BlackRock Inc. BLK | 4,643,736 9.600% | 501,208 (+12.10%) | Filing |
| 2023-01-25 10:36 am Purchase | 2022-12-31 | 13G | Nurix Therapeutics, Inc. NRIX | BlackRock Inc. BLK | 4,142,528 8.800% | 1,594,667 (+62.59%) | Filing |
| 2022-02-04 4:12 pm Purchase | 2021-12-31 | 13G | Nurix Therapeutics, Inc. NRIX | BlackRock Inc. BLK | 2,547,861 5.700% | 2,547,861 (New Position) | Filing |